A Phase I study to investigate KH-001 in healthy males
This Phase I study evaluated an experimental medicine called KH-001 to find out how safe it is and how it behaves inside the human body. The trial involved 82 healthy men aged 18 to 64 at a specialist clinic in South Wales. Participants tested the drug either as a liquid drink or as a tablet that dissolves on the tongue. Some took a single dose, while others took repeated doses over several days. Doctors closely tracked heart health, blood pressure, blood and urine drug levels, and general mood. Because this was an early trial in healthy volunteers, participants did not receive any direct medical benefit. However, the results are vital to see whether KH-001 can move forward as a potential treatment for premature ejaculation. Medical staff monitored everyone around the clock during their stays to ensure their safety.
At a glance
What is this study about?
Researchers carried out this study to look at an experimental medicine called KH-001 besylate. Before any new drug can be given to patients with an illness, scientists must first test it in small groups of healthy volunteers. This early step, known as a Phase I trial, checks whether the medicine is safe, what side effects it might cause, and how much of it the body can comfortably tolerate.
The study explored how the drug travels through the body by measuring levels in blood and urine samples over time. Researchers tested different dose strengths and compared two ways of taking it: a liquid medicine swallowed as a drink, and a melt-in-the-mouth tablet. They also monitored routine body functions and checked participants' mood to ensure the drug did not cause emotional distress.
While healthy volunteers do not gain direct health benefits, their participation is essential for medical research. KH-001 is being developed as a potential future treatment for premature ejaculation, a common condition that can cause significant personal distress and relationship difficulties. Gathering this basic safety data is the vital first step toward discovering whether it could become a helpful prescription treatment.
Key takeaways
- Phase I safety trial testing an experimental drug called KH-001 in healthy men.
- Looked at how the body processes both a liquid drink and a melt-in-the-mouth tablet.
- Aimed at supporting the future development of treatments for premature ejaculation.
- Involved short overnight stays at an accredited medical unit in South Wales with 24-hour supervision.
- Volunteers received no personal health benefits, but their help was crucial for medical science.
Who may be eligible?
This trial was open to healthy men aged between 18 and 64 years old with a body mass index (BMI) between 18 and 30 kg/m². Volunteers needed to be in good general health, confirmed by standard blood tests, urine checks, blood pressure readings, and an electrocardiogram (ECG) heart scan.
Because of unknown risks to an unborn child, women were not able to take part. Men with a female partner who could become pregnant had to agree to use reliable contraception, including condoms, throughout the trial and for at least three months after their final dose.
People could not join if they took regular prescription or over-the-counter medicines, had digestive disorders that might affect how drugs are absorbed, or had a history of drug or alcohol misuse. Tests for common viral infections, such as HIV and hepatitis, also had to be negative.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Male aged between 18 and 64 years old
- Generally healthy with no major ongoing medical conditions
- Body mass index (BMI) between 18 and 30 kg/m²
- Not currently taking regular prescription or non-prescription medicines
- Willing to use effective contraception (including condoms) if with a partner who could become pregnant
- Able to stay overnight at the clinic and attend follow-up checks
What does participation involve?
Taking part involved several stages over a few weeks. First, volunteers attended a screening appointment up to four weeks before receiving their medicine to confirm they were completely healthy. Depending on which group they joined, participants stayed overnight at a specialist clinic in South Wales for between two and six nights. During their stay, they received their study dose as either a liquid drink or a fast-dissolving tablet.
Clinical staff regularly checked blood pressure, pulse, and heart rhythms, and took routine blood and urine samples to see how quickly the body processed the drug. Participants were also asked simple questions about their mood and general wellbeing. Around five to seven days after their last dose, volunteers attended a short follow-up visit to make sure they remained in good health. In total, participation took between four and six weeks from the first check to the final visit.
Potential risks and benefits
Locations (1)
- Simbec Research LimitedCity onlyMid Glamorgan, Wales
Common questions
Why was this trial only open to men?
KH-001 is being developed as a treatment for premature ejaculation, a condition that affects men. In addition, early safety studies often restrict participation to avoid any potential, unknown risks to an unborn baby.
Did participants receive payment for taking part?
Phase I trials in healthy volunteers usually offer financial compensation for the time, travel, and overnight stays required, while all clinical care is provided free of charge.
Did everyone receive the active medicine?
Some participants may have received a dummy treatment known as a placebo. Comparing the real medicine with a placebo helps scientists understand which effects are truly caused by the drug.
How was safety monitored during the overnight stays?
Participants stayed in an accredited clinical unit with trained doctors and nurses present 24 hours a day, supported by emergency equipment and local hospital agreements.
What happens now that the study is finished?
Scientists analyse the data collected from blood samples, urine tests, and health checks to decide the best dose and form of the medicine for future clinical trials in patients.
How to find out more
Hans-Jürgen Gruss
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.